





## **MDMB-5Br-INACA**

Sample Type: **Drug Material** 

O N N N N H

Latest Revision: May 17, 2022

Date Received: March 11, 2022

Date of Report: May 17, 2022

#### 1. GENERAL INFORMATION

**IUPAC Name:** Methyl 2-[(5-bromo-1H-indazole-3-carbonyl)amino]-3,3-dimethyl-

butanoate

**InChI String:** InChI=1S/C15H18BrN3O3/c1-15(2,3)12(14(21)22-4)17-

13(20)11-9-7-8(16)5-6-10(9)18-19-11/h5-7,12H,1-

4H3,(H,17,20)(H,18,19)

**CFR:** Not Scheduled (05/2021)

CAS# Not Available

**Synonyms:** 5Br-MDMB-INACA, MDMB-5-bromo-INACA

Source: Indianapolis-Marion County Forensic Services Agency

**Appearance:** Plant-Like Material

*Important Note*: All identifications were made based on evaluation of analytical data (GC-MS and LC-QTOF-MS) in comparison to analysis of acquired reference material.

**Prepared By:** Alex J. Krotulski, PhD; Ryan Farrell; Kaitlin Schilde, MSFS; Melissa F. Fogarty, MSFS, D-ABFT-FT; Sara E. Walton, MS; and Barry K. Logan, PhD, F-ABFT

#### 2. CHEMICAL AND PHYSICAL DATA

#### 2.1 CHEMICAL DATA

| Form | Chemical<br>Formula    | Molecular<br>Weight | Molecular Ion<br>[M <sup>+</sup> ] | Exact Mass<br>[M+H] <sup>+</sup> |
|------|------------------------|---------------------|------------------------------------|----------------------------------|
| Base | $C_{15}H_{18}BrN_3O_3$ | 368.2               | 367                                | 368.0604                         |

#### 3. BRIEF DESCRIPTION

MDMB-5Br-INACA is classified as a synthetic cannabinoid. Synthetic cannabinoids have been reported to cause psychoactive effects similar to delta-9-tetrahydrocannabinol (THC). Synthetic cannabinoids have caused adverse events, including deaths, as described in the literature. However, little to no information is currently known about the activity, potency, and/or toxicity of MDMB-5Br-INACA. New synthetic cannabinoids continue to emerge among the recreation drug supply internationally, seemingly as replacements after a synthetic cannabinoid class-wide ban implemented by China in July 2021 which included most traditional indole and indazole structural scaffolds. Many of these new synthetic cannabinoid analogues are unstudied with pharmacological and human effects undetermined. Currently, MDMB-5Br-INACA is not a scheduled substance in the United States.

#### 4. ADDITIONAL RESOURCES

1. Cui-Mei Liu, Zhen-Dong Hua, Wei Jia, Tao Li. (2021) Identification of AD-18, 5F-MDA-19, and pentyl MDA-19 in seized materials after the class-wide ban of synthetic cannabinoids in China. *Drug Test Anal*. <a href="https://doi.org/10.1002/dta.31858">https://doi.org/10.1002/dta.31858</a>

https://www.caymanchem.com/product/36757/mdmb-5br-inaca

#### 5. QUALITATIVE DATA

#### **5.1 GAS CHROMATOGRAPHY MASS SPECTROMETRY (GC-MS)**

**Testing Performed At:** The Center for Forensic Science Research and Education at the

Fredric Rieders Family Foundation (Willow Grove, PA)

**Sample Preparation:** Dilution in methanol (Indianapolis-Marion County Forensic

Services Agency)

**Instrument:** Agilent 5975 Series GC/MSD System

**Column:** Agilent J&W DB-1 (12 m x 200  $\mu$ m x 0.33  $\mu$ m)

Carrier Gas: Helium (Flow: 1.46 mL/min)

**Temperatures:** Injection Port: 265 °C

Transfer Line: 300 °C

MS Source: 230 °C

MS Quad: 150 °C

Oven Program: 50 °C for 0 min, 30 °C/min to 340 °C for 2.3 min

**Injection Parameters:** Injection Type: Splitless

Injection Volume: 1 µL

**MS Parameters:** Mass Scan Range: 40-550 m/z

Threshold: 250

**Retention Time:** 7.82 min


**Standard Comparison:** Reference material for MDMB-5Br-INACA (Batch: 0643322-2)

was purchased from Cayman Chemical (Ann Arbor, MI, USA). Analysis of this standard resulted in positive identification of the analyte in the exhibit as MDMB-5Br-INACA based on retention

time (7.80 min) and mass spectral data.


(https://www.caymanchem.com/product/36757/mdmb-5br-inaca)

## Chromatogram: MDMB-5Br-INACA



Additional peaks in chromatogram: internal standard (5.69 min)

EI (70 eV) Mass Spectrum: MDMB-5Br-INACA



# 5.2 LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY (LC-QTOF)

**Testing Performed At:** The Center for Forensic Science Research and Education at the

Fredric Rieders Family Foundation (Willow Grove, PA)

**Sample Preparation:** Dilution in methanol (Indianapolis-Marion County Forensic

Services Agency) followed by 1:100 dilution of GC-MS sample in

mobile phase (CFSRE)

**Instrument:** Sciex TripleTOF® 5600+, Shimadzu Nexera XR UHPLC

**Column:** Phenomenex® Kinetex C18 (50 mm x 3.0 mm, 2.6 µm)

**Mobile Phase:** A: Ammonium formate (10 mM, pH 3.0)

B: Methanol/acetonitrile (50:50)

Flow rate: 0.4 mL/min

**Gradient:** Initial: 95A:5B; 5A:95B over 13 min; 95A:5B at 15.5 min

**Temperatures:** Autosampler: 15 °C

Column Oven: 30 °C

Source Heater: 600 °C

**Injection Parameters:** Injection Volume: 10 μL

**QTOF Parameters:** TOF MS Scan Range: 100-510 Da

Precursor Isolation: SWATH® acquisition (27 windows)

Fragmentation: Collison Energy Spread (35±15 eV)

MS/MS Scan Range: 50-510 Da

**Retention Time:** 9.01 min


**Standard Comparison:** Reference material for MDMB-5Br-INACA (Batch: 0643322-2)

was purchased from Cayman Chemical (Ann Arbor, MI, USA). Analysis of this standard resulted in positive identification of the analyte in the exhibit as MDMB-5Br-INACA based on retention

time (9.06 min) and mass spectral data.


(https://www.caymanchem.com/product/36757/mdmb-5br-inaca)

## **Extracted Ion Chromatogram: MDMB-5Br-INACA**




[peak at 8.82 mins has identical MS data to MDMB-5Br-INACA, 9.01 min]

## **TOF MS Spectra: MDMB-5Br-INACA**



### TOF MS/MS Spectra: MDMB-5Br-INACA



#### 6. FUNDING

NPS Discovery at the Center for Forensic Science Research and Education (CFSRE) is supported in part by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 2020-DQ-BX-0007, "Real-Time Sample-Mining and Data-Mining Approaches for the Discovery of Novel Psychoactive Substances (NPS)"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect those of the Department of Justice.